Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies

doi:10.1016/S0092-8674(85)80050-7

Cell

Volume 41, Issue 3, July 1985, Pages 695-706

https://doi.org/10.1016/S0092-8674(85)80050-7 Get rights and content

Summary

Exposure of neu-oncogene-transformed NIH 3T3 cells to monoclonal antibodies reactive with the neu gene product, p185, results in the rapid and reversible loss of both cell-surface and total cellular p185. Although not directly cytotoxic, monoclonal anti-p185 antibody treatment causes neu-transformed NIH 3T3 cells to revert to a nontransformed phenotype, as determined by anchorage-independent growth. Isotype matched control antibodies of an unrelated specificity do not affect p185 levels or colony formation in soft agar by neu-transformed NIH 3T3 cells. Soft agar colony formation by NIH 3T3 cells transformed by ras oncogenes is not affected by anti-p185 antibody treatment. Anchorage-independent growth of cells from the ethyl nitrosourea-induced rat neuroblastoma line in which neu was originally detected by DNA transfection is also inhibited in the presence of anti-p185 monoclonal antibodies. Collectively, these results suggest that p185 is required to maintain transformation induced by the neu oncogene.

References (55)

BaumannH. et al.
Metabolic fate of cell surface glycoproteins during immunoglobulin-induced internalization
Cell
(1980)
BeugH. et al.
Temperature-sensitive mutants of avian erythroblastosis virus: surface expression of the erbB product correlates with transformation
Cell
(1984)
BradfordM.M.
A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of proteindye binding
Anal. Biochem.
(1976)
CarpenterG.
Properties of the receptor for epidermal growth factor
Cell
(1984)
CarrollA.M. et al.
Monoclonal antibodies to tissue-specific cell surface antigens. I. Characterization of an antibody to a prostate tissue antigen
Clin. Immunol. Immunopathol.
(1984)
GillG.N. et al.
Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factorstimulated tyrosine protein kinase activity
J. Biol. Chem.
(1984)
PadhyL.C. et al.
Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas
Cell
(1982)
SeftonB.M. et al.
Evidence that the phosphorylation of tyrosine is essential for cellular transformation by Rous sarcoma virus
Cell
(1980)
StilesC.D.
The molecular biology of platelet-derived growth factor
Cell
(1983)
AlbinoA.P. et al.
Transforming ras genes from human melanoma: a manifestation of tumor heterogeneity?
Nature
(1984)

BadgerC.C. et al.

Therapy of murine leukemia with monoclonal antibody against a normal differentiation antigen

J. Exp. Med.

(1984)

BishopJ.M.

Cellular oncogenes and retroviruses

Ann. Rev. Biochem.

(1983)

BishopJ.M. et al.

Function and origins of retroviral transforming genes

BoyseE.A. et al.

Modification of the antigenic structure of the cell membrane by thymus-leukemia (TL) antibody

CarpenterG. et al.

Epidermal growth factor

Ann. Rev. Biochem.

(1979)

CollinsS. et al.

Amplification of endogenous mycrelated DNA sequences in a human myeloid leukemia cell line

Nature

(1982)

CooperC.S. et al.

Molecular cloning of a new transforming gene from a chemically transformed human cell line

Nature

(1984)

CooperG.M.

Cellular transforming genes

Science

(1982)

CzechM.P. et al.

Interrelationships among receptor structures for insulin and peptide growth factors

de KleinA. et al.

A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelogenous leukemia

Nature

(1982)

DerC.J. et al.

Transforming genes of human bladder and lung carcinoma lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses

DownwardJ. et al.

Close similarity of epidermal growth factor receptor and v-erbB oncogene protein sequences

Nature

(1984)

DrebinJ.A. et al.

Monoclonal antibodies identify a cell surface antigen associated with an activated cellular oncogene

Nature

(1984)

EdelmanG.M.

Surface modulation in cell recognition and cell growth

Science

(1976)

EvaA. et al.

Cellular genes analogous to retroviral onc genes are transcribed in human tumor cells

Nature

(1982)

FreedmanV. et al.

Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium

Cell

(1974)

Cited by (373)

Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma
2022, Annals of Oncology
ERBB2 is the most prominent therapeutic target in gastroesophageal adenocarcinoma (GEA). For two decades, trastuzumab was the only treatment available for GEA overexpressing ERBB2. Several drugs showing evidence of efficacy over or in complement to trastuzumab in breast cancer failed to show clinical benefit in GEA. This resistance to anti-ERBB2 therapy is peculiarly recurrent in GEA and is mostly due to tumor heterogeneity with the existence of low expressing ERBB2 tumor clones and loss of ERBB2 over time. The development of new ERBB2 testing strategies and the use of antibody-drug conjugates having a bystander effect are providing new tools to fight heterogeneity in ERBB2-positive GEA. Co-amplifications of tyrosine kinase receptors, alterations in mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K) signaling pathways and in proteins controlling cell cycle are well known to contribute resistance to anti-ERBB2 therapy, and they can be targeted by dual therapy. Recently described, NF1 mutations are responsible for Ras phosphorylation and activation and can also be targeted by MEK/ERK inhibition along with anti-ERBB2 therapy. Multiple lines of evidence suggest that immune mechanisms involving antibody-dependent cell-mediated cytotoxicity are preponderant over intracellular signaling in anti-ERBB2 therapy action. A better comprehension of these mechanisms could leverage immune action of anti-ERBB2 therapy and elucidate efficacy of combinations associating immunotherapy and anti-ERBB2 therapy, as suggested by the recent intermediate positive results of the KEYNOTE-811 trial.
The HER family as therapeutic targets in colorectal cancer
2022, Critical Reviews in Oncology/Hematology
The human epidermal growth factor receptor (HER, ErbB) family has four members, epidermal growth factor receptor (EGFR), HER2, HER3, and HER4. Although distinct in ligands and functions, all of the HER family members are receptor tyrosine kinases playing important roles in the pathogenesis of cancers. In the era of precision medicine, the HER family is one of the most important and successful cancer therapeutic targets, hallmarked by the approval of anti-EGFR therapies for the treatment of colorectal cancer and non-small cell lung cancer, and anti-HER2 therapies for the treatment of breast cancer and gastric cancer. This review briefly discusses how HER family members were discovered, their functions and roles in cancer, and most importantly, the developmental history and recent updates of therapies targeting HER family members, with colorectal cancer as a focus. We also discussed the patient selection and drug resistance to anti-EGFR therapies in the treatment of colorectal cancer.
Precision medicine
2021, The Era of Artificial Intelligence, Machine Learning, and Data Science in the Pharmaceutical Industry
It has been shown that several diseases have genetic basis and bias. These changes such as mutations, copy number alteration, epigenetic changes, and RNA expression cause disease progression, adverse events, and drug resistance, among other physiological and pharmacological interferences to the patient. A key example here is tumor growth and metastasis to other organs. While medicine has always considered the individual patient’s situation and there is a long history of segmenting patient populations by data, the recent explosion of rich biomedical data and informatic tools has galvanized the idea of “precision medicine.” By identifying fundamental patient types, we can deliver “the right treatment for the right patient at the right time.” Similar ideas can be found in the “5 R” framework for effective drug development, which emphasizes that a drug must reach the right target, in right tissue, with the right safety profile in the right patient. Treatments can be selected that are most likely to help patients based on a molecular understanding of their disease, rather than a possibly deceptive clinical presentation. This is especially keen for the increasing number of high cost therapies with great variation in patient-to-patient outcomes, for example, checkpoint inhibitors. If we can correctly partition a patient population, we get more homogenous cohorts with shared disease states for mechanistic investigation. If we can subtype a trial population to one where a candidate drug will be effective, we can reduce the trial size. If smaller and rarer disease populations—often unrecognized or neglected in therapy development—can be detected within larger populations, they can be investigated and treated appropriately.
In vivo modeling of the EGFR family in breast cancer progression and therapeutic approaches
2020, Advances in Cancer Research
Modeling breast cancer through the generation of genetically engineered mouse models (GEMMs) has become the gold standard in the study of human breast cancer. Notably, the in vivo modeling of the epidermal growth factor receptor (EGFR) family has been key to the development of therapeutics and has helped better understand the signaling pathways involved in cancer initiation, progression and metastasis. The HER2/ErbB2 receptor is a member of the EGFR family and 20% of breast cancers are found to belong in the HER2-positive histological subtype. Historical and more recent advances in the field have shaped our understanding of HER2-positive breast cancer signaling and therapeutic approaches.
Regulated phosphosignaling associated with breast cancer subtypes and druggability
2019, Molecular and Cellular Proteomics
Citation Excerpt :
These phosphosites may alter the biochemical properties of the active site and affect the activity level of the corresponding kinase. To inform targeted treatment, druggability analysis has traditionally focused on detecting single activating events, for example EGFR mutation, PIK3CA mutation, and ERBB2 amplification (49, 50). Although these events can predict treatment response, we reason that co-occurrence of elevated kinase-substrate phosphorylation can confirm aberrant activation and reveal new treatment options.
Aberrant phospho-signaling is a hallmark of cancer. We investigated kinase-substrate regulation of 33,239 phosphorylation sites (phosphosites) in 77 breast tumors and 24 breast cancer xenografts. Our search discovered 2134 quantitatively correlated kinase-phosphosite pairs, enriching for and extending experimental or binding-motif predictions. Among the 91 kinases with auto-phosphorylation, elevated EGFR, ERBB2, PRKG1, and WNK1 phosphosignaling were enriched in basal, HER2-E, Luminal A, and Luminal B breast cancers, respectively, revealing subtype-specific regulation. CDKs, MAPKs, and ataxia-telangiectasia proteins were dominant, master regulators of substrate-phosphorylation, whose activities are not captured by genomic evidence. We unveiled phospho-signaling and druggable targets from 113 kinase-substrate pairs and cascades downstream of kinases, including AKT1, BRAF and EGFR. We further identified kinase-substrate-pairs associated with clinical or immune signatures and experimentally validated activated phosphosites of ERBB2, EIF4EBP1, and EGFR. Overall, kinase-substrate regulation revealed by the largest unbiased global phosphorylation data to date connects driver events to their signaling effects.
Breast biomarker immunocytochemistry
2018, The Breast: Comprehensive Management of Benign and Malignant Diseases
Organization, more than 20 morphologic subtypes of breast cancer have been recognized. By gene expression, invasive breast cancer is classified into at least four major subtypes; luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)/neu-positive, and triple-negative cancers. The biology and the prognosis of these subtypes are vastly different. It is well recognized that genetic profiles of these cancer subtypes are also interlinked with the traditional breast biomarkers. According to the US National Institutes of Health's Working Group and Biomarkers Consortium, a biomarker is a characteristic that is objectively measured as an indicator of normal biological processes, pathogenic processes, or a pharmacologic response to a therapeutic intervention.

View all citing articles on Scopus

View full text

Cell

Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies

Summary

Cell

Cell

Anal. Biochem.

Cell

Clin. Immunol. Immunopathol.

J. Biol. Chem.

Cell

Cell

Cell

Transforming ras genes from human melanoma: a manifestation of tumor heterogeneity?

Nature

Therapy of murine leukemia with monoclonal antibody against a normal differentiation antigen

J. Exp. Med.

Cellular oncogenes and retroviruses

Ann. Rev. Biochem.

Function and origins of retroviral transforming genes

Modification of the antigenic structure of the cell membrane by thymus-leukemia (TL) antibody

Epidermal growth factor

Ann. Rev. Biochem.

Amplification of endogenous mycrelated DNA sequences in a human myeloid leukemia cell line

Nature

Molecular cloning of a new transforming gene from a chemically transformed human cell line

Nature

Cellular transforming genes

Science

Interrelationships among receptor structures for insulin and peptide growth factors

A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelogenous leukemia

Nature

Transforming genes of human bladder and lung carcinoma lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses

Close similarity of epidermal growth factor receptor and v-erbB oncogene protein sequences

Nature

Monoclonal antibodies identify a cell surface antigen associated with an activated cellular oncogene

Nature

Surface modulation in cell recognition and cell growth

Science

Cellular genes analogous to retroviral onc genes are transcribed in human tumor cells

Nature

Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium

Cell